Clinical Trial Update: A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, reactogenicity and immunogenicity of GSK2838497A in current and former smokers has completed. The vaccine targets non-typeable …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Disorders

Drugs mentioned

• GSK2838497A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Disorders | Phase 1 | Status: COMPLETED